Latest European Markets News

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Comms Group Limited reported record FY26 revenue and EBITDA growth, driven by organic expansion and TasmaNet acquisition, while progressing the $30m sale of its ICT business to streamline operations and support shareholder returns.

Aurora Labs posted a 36% increase in net loss to $5.1 million for FY2026 despite securing key defence contracts and partnerships. The company is transitioning from R&D to early commercialisation of its micro gas turbine propulsion systems, backed by a $5.5 million capital raise and government grants.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

Skellerup Holdings delivered a tenth consecutive year of EBIT growth with a 14% rise to NZD 89.3 million and expanded its climate initiatives, reporting a 24% jump in net profit to NZD 67.7 million.

Atomo Diagnostics has appointed Dr Cheri Walker as interim CEO, replacing founder John Kelly who steps down after 15 years. The leadership change aligns with the company's shift towards commercial growth in the US and Europe.

Osmond Resources has reinforced the continuity of high-grade critical minerals at its Orión project in Spain, with drill hole SOR-07A delivering promising assay results. The company is on track to release its maiden Mineral Resource Estimate and Scoping Study by Q3 2026, supported by robust mineral processing testwork and a new Frankfurt listing.

Brazilian Rare Earths (ASX: BRE) has delivered a striking scoping study for its Rocha da Rocha Rare Earths Province in Brazil, anchored by the Monte Alto deposit’s world-class 11.3% TREO grade, projecting robust economics and a low-cost production path.

Amotiv Limited (ASX: AOV) delivered a solid FY26 with a $75.1 million net profit, reversing last year’s loss, underpinned by 2.7% revenue growth and strong cash conversion. The company declared a fully franked 23 cent final dividend and advanced its Amotiv Unified transformation and climate initiatives.

Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.